Low-molecular-weight heparins (LMWH) are widely used as antithrombotic prophylactic pharmaceutical agents in orthopedic and general surgery. Their antithrombotic characteristics are expressed by plasma mediators such as anti-Xa, anti-Ila, and increased release of tissue factor pathway inhibitor (TFPI) from vascular endothelium. The purpose of this clinical research is to study the relation between plasma levels of these mediators and postoperative bleeding.
Those who did not bleed (hemoglobin drop was less than 5 g/dL) (n = 28) had a ratio increase (if any) of less than 50%.
However, the authors did not observe any statistical relationship between anti-Xa, anti-IIa, or prothrombin time and postoperative bleeding in patients receiving LMWH for deep vein thrombosis prophylaxis in orthopedic and general surgery patients. The authors recommend a pre-and postoperative ratio level measurement whenever major bleeding is anticipated, as adjustments of LMWH dose or frequency might be necessary. Key Words: Tissue factor pathway inhibitor&mdash;Enoxaparin&mdash; Postoperative bleeding. The safest, most effective method of deep vein thrombosis (DVT) prophylaxis in orthopedics and general surgery is controversial. Low-molecular-weight heparins (LMWH) are widely used as effective prophylaxis for DVT, replacing heparin and Coumadin in many centers, despite the fact that no routine laboratory tests are available to monitor potential bleeding complications. LMWH, however, has effects on plasma proteins and other mediators which are the determinant factors in maintaining an antithrombotic status (1) (2) (3) . These factors include anti-Xa, anti-Ila, and tissue factor pathway inhibitor (TFPI). Anti-Xa and anti-IIa are patient dependent and have no relation to bleeding (4), so their levels cannot be reliably used to monitor postoperative bleeding (5, 6) . On the other hand, TFPI (7-9) has been used to measure the antithrombotic effects of LMWH in a doseand time-dependent manner in animal models 1 and healthy volunteers (3) . I, normally present in plasma and in vascular endothelial cells, maintains an equilibrum between antithrombotic and hemorrhagic effects & d q u o ;
(10-12)(i.e., while TFPI inhibits tissue factor to prevent vascular thrombosis, it does not cause bleeding, in normal physiologic settings). When LMWH is used, it will increase plasma TFPI levels and bleeding will increase to about 10%, especially when started earlier than 24 hours after surgery (13, 14) . It is expected that ~9~1~-~?~'~ of patients undergoing total knee and hip arthroplasty will require blood transfusion (15) (16) (17) . The definition of bleeding as major or minor or clinically significant varies tremendously in the literature. We elected to use a de-crease in hemoglobin (Hb) of more than 5 g/dL, to be clinically significant. Our average ~ati~i~t's Hb was 13'± 1.5 g/dL and a decrease to 8 g/dL entailed a surgical intervention or transfusion in our cases. In addition, the ' clinically acceptable postoperative decrease in hemoglobin in patients on LMWH is less than 5 g/dL (18) (19) (20) (21) (22) (23) (24) .
With enoxaparin being widely used and the first LMWH to be approved for orthopedic use, we examined the bleeding complications of enoxaparin in relation to free TFPI, total TFPI, anti-Xa, and anti-Ila levels in a ' prospective study of 41 consecutive patients undergoing hip (n = 14) or knee art~tr~plasty (n = 22) and colectomy (n = 5) who received the standard enoxaparin dose. Postoperatively, we have observed that when plasma free TFPI/totat TFPI ratios increased by >60%, the hemoglobin levels dropped more than 5.0 g/dL. This relationship was statistical significant (P < 0.001), while anti-Xa or HeptestO (7,8) (a test that reflect mainly anti-Xa and anti-If activities) did not show a statistical relationship. This unique TFPI relationship with postoperative bleeding has a potential use for monitoring and predicting the degree of antithrombotic effects of enoxaparin -in patients undergoing hip or knee arthroplasty and colectomy.
METHODS
A prospective double-blinded clinical study was conducted on 4 patients ( after orthopedic surgery and 40 mg SC, QD, starting before skin incision for general surgery). The early ini-Ciutian of prophylaxis was to give a greater protection against DVT (25), risking more postoperative bleeding complications, which were studied and monitored. Aii ' patients si~ned ~:n IR~-~ppro~~d consent form. The body weight ranged from 110 to 250 pounds, 22 patients had primary total knee arthroplasty, 10 had primary total hip arthroplasty, 4 had revision hip arthroplasty, and 5 had colon resection (Table 1 ). Exclusion criteria were pregnancy ; active bleeding, especially peptic ulcer and intracranial bleedings; allergy to enoxaparin, renal failure requiring dialysis; and established DVT and platelet levels <50,000. All patients stayed for 7 days in the hospital. TFPI (total and free), anti-Xa, and HeptestO levels were determined pr~c~perativeiy and at 3-4 hours after enoxaparin injection postoperatively, for days 0, 1, 3, 5, and 7. Pre-and postoperative Hb, PT, PTT, and platelet counts were measured on site, while plasma obtained ' from citrated whole blood were frozen and sent to Dr. J.
Fareed (Loyola University) for analysis of TFPI, anti-Xa, and Heptest4'. The clot-based Heptest° was obtained from Heamachem (St. Louis, MO). Anti-Xa was per-' formed by an in-house method from Loyola (Walenga et al.). TFPI was performed by an ELISA technique (American Diagnostica; Greenwich, CT). Significant bleeding was defined by a decrease of Hb >5 g/dL from the preoperative levels (before the initiation of enoxaparin). To calculate the lowest hemoglobin level, each unit of blood transfused equates I g/dL to be subtracted from the post-transfusion Hb level.
The changes in postoperative free/total TFPI ratios with Hb levels were documented for statistical analysis using the ANOVA test to compare the differences between the two groups of patients (bleeders vs. nonbleeders). Sigma Stat (Jandel scientific software) was used for all statistical analyses. Values are expressed as the mean ± SE changes in percent ratio of free to total TFPI.
RESULTS
Thirteen out of 41 patients (31.7%) had a Hb decrease of >5 g/dL. This high number was expected because enoxaparin was started immediately before surgery (in colon surgery) or immediately after surgery (in orthopedic patients). Two out of the 41 patients had unexpected intraoperative bleeding and received blood transfusion (a revision hip and a knee case). Hemoglobin was measured again in the recovery room to serve as a control before the initiation of enoxaparin. Out of 246 free/total TFPI I ratio level readings, a total of six readings were omitted from the study (not more than two per patient) because the TFPI levels were not drawn at the 3to 4-hour period after enoxaparin. injection.
When the free/total TFPI ratio increased to more than 60% from the preoperative ratio levels, significant bleeding >5 g/dL was observed (Fig. 1 ), The lowest increases in free/total TFPI ratio in the bleeding group was 60.l%, while the highest increase in free/total TFPI levels in the nonbleeding group was 49.7% (Table 2 ). It seems that if ' the increase in the ratio is less than 50% of preoperative levels, significant bleeding did not occur (Fig. 1) .
The mean percent changes ± SE (SEM) for those who had significant bleeding were (Figs. 1 and 2): postop day 0 = ~72:40°~~ ~-~4:1, day 1 = ~~.3b~lv ± 33.85, day 3 = 83.11%:t 19, day 5 = ~4:~~°~~ ± 22.59, and day 7 = 61.07% ±26. For nonbleeders, the percent changes were: postop day 0 = -~.33~~ ± 5.85, day 1 = fl.15~g ± 5.63, day 3 = 5.91% ± 7.42, day 5 = -7.36% ± 6.35, and day 7 = -6.25% ± 6.30. The patients who bled (hemoglobin drop >5 g/dL) had a significantly higher increase in the ratio of free/total TFPI for each equivalent postoperative day (P ~ 0.001).
As confirmed by previous studies, PT and PTT did not show any significant correlation with bleeding from enoxaparin, though they were mildly prolonged in some patients. Heptest~ baseline levels were 16.7 ± 2.5 then increased to a plateau of 50.1 I -~ 3.5 at postop day 0 in all patients (bleeders and nonbleeders) ( Fig. 3 ). Anti-Xa levels were zero preoperatively in all patients then they steadily increased to an average of ~~.~ ~ 2.3 at postoperative day 3 (Fig. 4 ). Although Heptest@ levels increased with the administration of enoxaparin, they did not correlate with bleeding. Also, there was no statistical difference between both groups (bleeders and nonbleeders). Anti-Xa levels, on the other hand, increased steadily with enoxaparin administration but with no statistical difference between the bleeder and the nonbleeder groups (Fig. 4 FIG. 1. The percent changes the ratios between the free TFPI and total TFPI for patients who had significant bleeding and those who did not are significant at P < 0.001 . nb, nonbleeders; bi, bleeders; C, percent change in the ratio. Numbers 0, 1, 3, 5, and 7 are the days before surgery and the subsequent days.
Values are mean ± SE. he total percent increase is listed in the last column. Drop in hemoglobin is next to it for comparison. Rows 29-~:i show major bleeding, i.e., hemoglobin drop of more than 5 gm/d!.
HGB, hemoglobin; TFPI, tissue factor pathway inhibitor. ' 
DISCUSSION
Penopcmtive and hip arthroplasty blood loss after LMWH (26) is expected to drop hemoglobin levels by an average of 2 g/dL as compared to preoperative levels with an average of 2-3 units of blood transfused (equating a 2-3 g/dL of hemoglobin) (18) (19) (20) (21) (22) (23) (24) . That is to say the total expected hemoglobin drop averages 4-5 g/dL. This was another reason why we chose a hemoglobin cutoff of more than 5 g/dL to be significant (i.e., a bleeder).
LMWH can cause bleeding through its direct anti-Xa (80-145 U/mg) and anti-factor II (35-45 U/mg) effects on the coagulation cascade (27) . As with other studies (4-6,28-31), we observed that anti-Xa levels and HeptestO have no correlation with postoperative bleeding. One reason is that anti-Xa levels do not parallel their antithrombotic activity (30, 32) , and their level varies with calcium concentration (20). However, LMWH can also cause bleeding through releasing TFPI from the vascular endothelium, in a dose-and time-dependent manner (1, 3, 33) . TFPI accounts for 70% of heparin antithrombotic activity (27, (34) (35) (36) (37) by inhibiting tissue factor, thrombin, protein C, and factor Xa, especially in the presence of LMWH (5, 33, (38) (39) (40) (41) (42) (43) (44) . TFPI) increase (Fig. 2} * When that ratio increases by >60%, th~n bt~~din~ will be more significant, dropping the hemoglobin to more than 5 gldL (P ~ 01.001). When an increase of protein-bound TFPI is out of proportion to the free TFPI increase, then not much of the free TFPI ' (active form) is consumed in neutralizing tissue factor and is thus converted to protein-bc~und iTFPI (inactive form) and therefore bleeding is not expected.
This unique correlation between the TFPI ratios and postoperative bleeding has not been published before.
CONCLUSION
To define an appropriate range of TFPI levels after enoxaparin administration does not necessarily imply serial laboratory monitoring for optimal therapy and clinical outcome. Nevertheless; one or two TFPI measurements may give us an idea of the levels we should avoid, to prevent undue postoperative bleeding complication (Figs. and 6). This may prove to be important for surgeons using LMWH as prophylaxis in hip or knee and colon surgery.
We recommend a preoperative free/total TFPI ratio measurement and another postoperative ratio measurement whenever bleeding is anticipated to see if there is a significant increase in that ratio. Minor adjustments of LMWH dose or frequency guided by the ratio changes of free to total TFPI might be all that is needed to prevent major bleeding (i.e., a decrease of more than 5 g/dL of hemoglobin). However, in order to determine whether adjustments of LMWH dose in such patients will increase the DVT incidence, another larger study will be necessary. 
